Bionano Genomics Inc.
12/02/2024 | Press release | Distributed by Public on 12/02/2024 15:55
Proxy Results Form 8 K
Item 5.07 Submission of Matters to a Vote of Security Holders.
On November 27, 2024, Bionano Genomics, Inc. (the "Company") held its 2024 Special Meeting of Stockholders (the "Special Meeting"), which had been previously adjourned for lack of quorum on October 2, 2024 and October 30, 2024. As of August 12, 2024, the record date for the Special Meeting (the "Record Date"), 85,997,130 shares of the Company's common stock were outstanding and entitled to vote at the Special Meeting. A summary of the matter voted upon by stockholders at the Special Meeting is set forth below.
A total of 30,467,764 shares of the Company's common stock were present at the Special Meeting in person, by virtual attendance, or by proxy, which represents approximately 35.42% of the shares of the Company's common stock outstanding as of the Record Date.
Proposal 1. Approval of the Issuance of Shares of Common Stock Issuable Upon Exercise of Warrants.
The Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 35,026,272 shares of common stock issuable upon the exercise of certain Series A warrants and Series B warrants issued in connection with a private placement pursuant to the securities purchase agreement, dated July 4, 2024, between the Company and certain institutional investors thereto. The final voting results are as follows:
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
22,919,968
|
6,162,679
|
1,385,117
|
0
|